Newcastle life sciences firm SkinBioTherapeutics expects larger revenues and narrowed losses, it has told investors.
The skin health products specialist gave a trading update in which it said unaudited revenues for the year to the end of June are expected to be between £4.5m-£4.8m, and unadjusted losses between £200,000 and £400,000, compared with £2.2m in 2024. The gains come on the back of acquisitions SkinBioTherapeutics has made, including Dermatonics, a provider of products including heal balm, treatment for warts and verrucas and dry skin relief.
Bosses said the improved results come after a full year's trading of Dermatonics and eight months' trading of Bio-Tech Solutions (BTS)- the Yorkshire-based health, hygiene and personal care products company that SkinBioTherapeutics snapped up at the end of last year. Sales of AxisBiotix - the firm's psoriasis-fighting food sachet product - was also said to have driven the results.
Investors were told revenues were slightly lower than market expectations thanks to the timing of orders for Dermatonics and BTS, with a significant amount coming post year end. Meanwhile cash at the end of June was better than expected at £4.8m, up from £1.2m at the end of December, which SkinBioTherapeutics said reflected June's share offer which generated about £4.2m to support the firm's agreement with Superdrug which will see AxisBiotix rolled out in its stores from next month.
The sachets are initially due to go out in Superdrug stores that have typically higher sales of medicated skincare products, before becoming available in all of the chain's º£½ÇÊÓƵ stores in Spring 2026. SkioBioTherapeutics plans to make the product available in a capsule or gum format in the long term, with work to focus on new formulations and the purchase of new capsule making and blister-packaging equipment.
Stuart Ashman, CEO of SkinBioTherapeutics, said: "The past 12 months have marked a distinct change in the operations of the company, driven by two acquisitions, the launch of Zenakine by Croda and the signing of a significant commercial deal with Superdrug to launch AxisBiotix on the º£½ÇÊÓƵ high street. Financially, we are also in a very different place, achieving c.4x the revenues relative to 2024, nearing profitability and have a strong cash balance.
"Compared to where we were only five years ago, where our majority focus was around research and development, we have come a long way. We strongly believe that the increased interest by consumers and the marketplace in the role of the microbiome on our skin health means that we are very well placed to scale rapidly and achieve significant value for shareholders."
